ReviewCurrent oncology (Toronto, Ont.)2020

Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease.

S Perera et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.